
· Executive Brief
Group B Strep Awareness Month 2026
Move from recognition activity to a visible operating route with named owners and closed loops.

Leadership signal
Use Group B Strep Awareness Month to examine the system behind the message.
Leaders can use this window to test whether public information, service entry points, internal referrals, and follow-up responsibilities form one understandable route. The review should start with the experience of people using the system and the teams responsible for receiving them.
Start by distinguishing what is known from what the organization still needs to learn. A campaign plan, communication volume, or meeting count does not establish that a route is usable. Leaders need direct listening, clear ownership, locally defined measures, and a method for keeping exceptions visible.
Executive opening
GBS prevention works only when every handoff holds
Group B streptococcus prevention is one of the clearest examples in maternity care of a pathway that works only when every link holds. A pregnant patient must be offered a test at the right time, the laboratory must return an accurate result, the result must reach labor and delivery, and antibiotics must start early enough to matter. When any step fails, the gap often stays invisible until a newborn becomes ill. For executives, the useful question is not whether a protocol exists but how often each step happens on time.
The stakes remain real. In the UK and Ireland, about 1 in 1750 newborns develop early-onset GBS infection.[1] Nationwide Dutch surveillance found that infant GBS disease rose from 0.19 to 0.57 per 1000 live births between 1987 and 2023.[10] A Dutch cohort of 375 infants with GBS sepsis or meningitis reported mortality of 5% and complications in 59%.[8]
The operating failure is often not the absence of a policy but incomplete execution. In the same Dutch cohort, only 40% of mothers eligible for intrapartum prophylaxis received it.[8] At a Saudi academic center, 67.2% of colonized women received prophylaxis, but only 15.6% received it at least four hours before delivery.[9] These are handoff and timing failures that health-system leaders can see, measure and fix. Each step crosses a department boundary, which is why ownership matters more than awareness.
The sections below summarize recent peer-reviewed research on burden, screening, laboratory turnaround, intrapartum prophylaxis, equity, workforce and communication. They sit beside the executive guidance already on this page. Together they give maternity, laboratory, pharmacy and quality leaders a shared factual base for deciding where Group B Strep Awareness Month should focus improvement. The evidence comes from many countries, so local data are needed to confirm which of these gaps apply in a given system.
Current evidence
What the research says about burden, colonization and screening
Colonization is common and varies by setting and testing method. In Slovenia’s new organized screening program, culture detected GBS in 1,809 of 11,194 pregnancy episodes (16.1%) between July 2023 and January 2026.[2] In northern Guangdong, China, PCR screening at 35 to 37 weeks found a prevalence of 10.64% among 13,506 women.[7] Across five Western Australian maternity hospitals, an analysis of 22,417 births reported an overall colonization rate of 21.7%.[15]
Colonization is associated with adverse outcomes for both mother and newborn. In the Guangdong cohort, adverse pregnancy outcomes occurred in 31.25% of GBS-positive women compared with 14.31% of GBS-negative women.[7] After adjustment, colonization remained associated with preterm birth (odds ratio 3.04) and premature rupture of membranes (odds ratio 2.86).[7] Colonization was also associated with intrauterine infection (odds ratio 2.78).[7] In a Hong Kong hospital, the risk of neonatal sepsis was 5.45 times higher among women who screened positive than among non-carriers.[14]
Invasive infant disease has not disappeared. Dutch surveillance identified 2,212 infant episodes from July 1987 to June 2024, 59% of them early-onset disease.[10] Serotype III was the most common, at 61% of typed isolates.[10] In the prospective Dutch cohort from 2018 to 2024, 57% of 375 cases were early-onset disease, and 88% of infants recovered without abnormalities at discharge.[8] Complications occurred in 59% of infants, and serotype III was associated with meningitis and late-onset disease.[8] The authors concluded that risk-based prevention strategies miss many cases and show low adherence.[8]
Screening appears to protect newborns when it is carried out reliably. In the Hong Kong hospital, adherence to universal screening reached 97% a decade after the policy began.[14] Among vaginally delivered term infants of carriers, the risk of neonatal sepsis fell by 71% when prophylaxis was given four or more hours before birth.[14] Among term infants of carriers delivered by cesarean section, antenatal antibiotic treatment was associated with a 70% lower risk of neonatal sepsis.[14] That timing threshold turns the labor admission into a time-critical operating step.
Laboratory surveillance also informs stewardship. In the Slovenian program, resistance to clindamycin and erythromycin was found in 19.7% and 19.9% of isolates, with no penicillin or vancomycin resistance observed.[2] That pattern matters most for patients with a penicillin allergy label, for whom alternative antibiotics are often chosen.[13] Executives can treat colonization rates, timing and resistance as one connected dashboard rather than separate laboratory and obstetric reports.
Figure 1
Intrapartum prophylaxis delivery varies widely across settings
Percent of colonized or eligible women receiving intrapartum antibiotic prophylaxis, as defined in each study. Values are copied from the cited studies [7], [8], [9]; none is estimated.
Data note. These values come from different countries, years, populations and definitions (the Dutch figure is limited to mothers of infants who developed disease), so this is an indirect comparison that shows variation in execution, not a ranking of programs.
Limitation. Each value reflects its own denominator; the Dutch value describes a case cohort, while the others describe screened populations.
Figure data (4 rows)
| Measure | Value | Population, setting and year as reported | Source |
|---|---|---|---|
| Received prophylaxis at least four hours before delivery | 15.6% | 28 of 180 GBS-positive women, single academic center in Riyadh, July 2021 to December 2022 | [9] |
| Eligible mothers who received prophylaxis | 40% | Mothers of infants with culture-confirmed GBS disease, Netherlands, 2018 to 2024 | [8] |
| Received any prophylaxis | 67.2% | 121 of 180 GBS-positive women, same Riyadh cohort | [9] |
| GBS-positive women who received prophylaxis | 94.1% | 1,352 of 1,437 GBS-positive women, northern Guangdong, China, 2020 to 2025 | [7] |

Continuum of care
Where the pathway breaks between the swab and the delivery room
The GBS3 trial process evaluation shows each step of the pathway in numbers. Across maternity units in England and Wales, detailed data were collected for 9,179 women.[1] The cluster-randomized trial involves approximately 320,000 women from 80 maternity units.[1] Overall, 72% of women were offered a vaginal-rectal swab, and 82% of those offered accepted one.[1] Of women swabbed, 17% were positive, and 87% had a result available at least four hours before birth.[1]
Each percentage represents a handoff. A swab not offered is a prenatal visit gap, and a result not available in time is a laboratory and communication gap. A result that arrives after admission cannot help the delivery team decide on prophylaxis. The authors concluded that when testing is offered, it is accepted, performed and returned in time for most women.[1] In that trial, the largest single loss was therefore the offer itself, which is a design question for prenatal clinic workflow.[1]
Timing of prophylaxis is a separate failure point. In the Saudi cohort, 180 of 4,604 screened women were GBS-positive.[9] Although 67.2% of colonized women received prophylaxis, only 15.6% received it at least four hours before delivery.[9] The neonatal intensive care admission rate among their infants was 8.3%, and culture-positive sepsis occurred in 1.1%.[9] Perinatal outcomes were generally good regardless of antibiotic timing in this small cohort, so the finding is a process signal rather than proof of harm.[9]
Patients who arrive in labor without a result form another gap. In a French maternity unit, 3,448 women (23.0%) were not screened by culture, and intrapartum PCR identified 621 additional GBS cases (4.1%).[12] Of these, 327 (2.2%) were in women without prior culture screening.[12] These women would otherwise have entered labor with no usable result. No neonatal GBS infections were observed during the 2015 to 2020 study period.[12]
Closing the unknown-status gap need not expand antibiotic exposure. After a rapid PCR program began at a level 3 maternity center, only 0.76% of women had unknown GBS status at delivery in 2022.[4] Neonatal antibiotic use fell significantly (odds ratio 0.64), while the share of women receiving prophylaxis held steady at 12.3% in 2019 and 12.2% in 2022.[4] The incidence of early-onset GBS sepsis in that population was 0.46 per 1,000 live births.[4] For leaders, the continuum is one shared process across clinic, laboratory, labor unit and nursery.
Figure 3
Why the pathway breaks
People
- Swab not offered at the prenatal visit
- Delivery teams unsure of status on arrival
- No pharmacist or allergy review of prophylaxis orders
Process
- Prophylaxis started less than four hours before birth
- No rapid testing route for patients without results
- Allergy history not clarified before labor
Technology
- Results not visible in the labor record
- Culture methods with long turnaround
- Manual plate reading that delays negative results
Environment
- Lower-resource laboratories with costly methods
- High-volume units with rapid labors
- Different care models with different workflows
Policy
- Risk-based strategies that miss cases
- Inconsistent allergy documentation standards
- No shared owner across clinic, laboratory and labor unit
Measurement
- Offer and completion rates not tracked
- Prophylaxis timing not reported
- Results not stratified by site, care model or insurance
Unranked qualitative cause-and-effect diagram for the outcome in the box: Colonized pregnant patients do not receive timely, appropriate intrapartum prophylaxis Causes are assembled from the cited literature [1], [2], [4], [5], [6], [8], [9], [11], [13], [15]; categories are not weighted and their order carries no meaning.
Data note. Qualitative; no frequencies are implied.
Limitation. Causes drawn from published studies may not all apply locally; validate them with frontline teams.
Figure data (6 rows)
| Category | Causes drawn from the cited literature |
|---|---|
| People | Swab not offered at the prenatal visit; Delivery teams unsure of status on arrival; No pharmacist or allergy review of prophylaxis orders |
| Process | Prophylaxis started less than four hours before birth; No rapid testing route for patients without results; Allergy history not clarified before labor |
| Technology | Results not visible in the labor record; Culture methods with long turnaround; Manual plate reading that delays negative results |
| Environment | Lower-resource laboratories with costly methods; High-volume units with rapid labors; Different care models with different workflows |
| Policy | Risk-based strategies that miss cases; Inconsistent allergy documentation standards; No shared owner across clinic, laboratory and labor unit |
| Measurement | Offer and completion rates not tracked; Prophylaxis timing not reported; Results not stratified by site, care model or insurance |
Access
Laboratory capacity, turnaround and access to timely results
Result turnaround determines whether screening can guide care in labor. In a Thai study of 174 women in labor with risk factors, real-time PCR detected GBS in 19.0% compared with 5.7% for culture.[5] PCR turnaround was 4 hours compared with 72 hours for culture.[5] For patients who present without a prenatal result, that difference decides whether testing can inform prophylaxis at all. Detection did not differ significantly between the risk-based antibiotic-indicated group and other high-risk women (27.3% versus 18.5%).[5] The authors suggested that other risk factors may deserve consideration for prophylaxis.[5]
Laboratory automation can shorten routine antenatal turnaround. At Geneva University Hospitals, direct chromogenic agar plating detected GBS in 13.2% of 9,107 specimens, the same rate as broth-enriched plating.[11] Sensitivity and specificity of direct plating against the enriched method were 98.3% and 99.7%.[11] With automated image analysis, the negative predictive value reached 100%, enabling automatic release of negative results within 24 hours.[11] Faster release of negatives can free laboratory staff for positive and complex specimens.
Method choice also shapes access in lower-resource settings. In Brazil, direct plating on chromogenic medium detected GBS in 6.5% of 1,128 samples compared with 2.7% for conventional selective broth.[6] The chromogenic method was faster and more cost-effective, although it failed when GBS density in the sample was low.[6] The authors argued that more feasible, cost-effective protocols could improve adherence to universal antenatal screening.[6] Low-cost methods also matter for safety-net laboratories in higher-income countries that face budget pressure.
Sensitivity choices matter as much as speed. In Slovenia, 111 of 1,809 culture-positive results were detected only after enrichment.[2] During a reflex molecular testing period, additional colonizations raised detection by about 10% relative to culture alone.[2] Each method trade-off changes how many colonized patients the pathway can identify.[2]
Economic modeling helps leaders weigh these options. A French decision-analytic model estimated that intrapartum PCR screening reduced early-onset GBS incidence by 14.14% compared with antepartum culture screening, with 21,910 women tested to prevent one case.[3] Applied to national deliveries, the model projected 32 prevented cases per year and annual savings of €895,711.[3] It also projected about two fewer GBS-related newborn deaths each year.[3] These are modeled estimates for one national health system, but they frame testing strategy as an investment decision rather than a laboratory preference.[3]
Executive guidance · System route
Connect the month to an accountable system route.
Use this route as a discussion framework. Replace each stage with the organization’s approved process, qualified roles, current service capacity, and applicable requirements. Do not infer a clinical protocol from the observance title.
The route at a glance
- Listen
- Clarify entry
- Coordinate the partner route
- Protect transitions
- Verify and learn
Reliability rule: Every stage needs a named owner, an observable status, an approved escalation path, and a defined signal that shows whether responsibility moved or remained unresolved.
Listen
Gather questions and friction points from people using the route, frontline teams, and community-facing staff. Separate observed barriers from assumptions.
Clarify entry
Publish a plain-language first step and identify who receives requests through each approved channel.
Coordinate the partner route
Align internal teams and external partners around one current message, real entry point, receiving owner, escalation path, and follow-through signal.
Protect transitions
Use acknowledgment and status visibility when responsibility moves between services, locations, or organizations.
Verify and learn
Review unresolved work, repeat contacts, and avoidable handoffs. Use the findings to improve the route rather than blame individuals.
Figure 2
The system route as one flow
The five stages of the system route described in this brief, drawn as one flow with a learning loop back to the start. The stages are the page’s original executive guidance, not a clinical protocol.
Data note. Shows sequence and handoffs only; it carries no counts or rates.
Limitation. Local processes may add, merge or reorder stages under organizational policy.
Figure data (5 rows)
| Stage | What the stage requires |
|---|---|
| Listen | Gather questions and friction points from people using the route, frontline teams, and community-facing staff. Separate observed barriers from assumptions. |
| Clarify entry | Publish a plain-language first step and identify who receives requests through each approved channel. |
| Coordinate the partner route | Align internal teams and external partners around one current message, real entry point, receiving owner, escalation path, and follow-through signal. |
| Protect transitions | Use acknowledgment and status visibility when responsibility moves between services, locations, or organizations. |
| Verify and learn | Review unresolved work, repeat contacts, and avoidable handoffs. Use the findings to improve the route rather than blame individuals. |
Equity and trust
Equity and safety in who is screened and how prophylaxis is chosen
Penicillin allergy labels create a hidden safety and equity issue. At a U.S. safety-net institution, 1,262 of 18,931 obstetric patients (6.7%) had a documented penicillin allergy.[13] Of patients with penicillin allergies, 196 were GBS-colonized.[13] Of 86 GBS-colonized patients with low-risk allergies, 54 (62.8%) received alternative antibiotics rather than standard prophylaxis.[13] The authors called for improved documentation of allergy type and severity and better antibiotic selection.[13]
That finding connects directly to laboratory data. Alternative agents face meaningful resistance, with clindamycin resistance at 19.7% in the Slovenian isolates, and erythromycin resistance was similar at 19.9%, so inaccurate allergy labels may leave some newborns with less reliable protection.[2][13] Allergy assessment during prenatal care is therefore a pathway step with an owner, not a detail left to the moment of admission.
Screening adherence also varied by model of care. In Western Australia, adherence was 68.76% in the midwifery-led model compared with 90.49% in the non-midwifery-led model.[15] Screening rates in the midwifery-led model trended down over the five years while remaining stable in the comparison group.[15] The difference points to how pathways are designed and supported for each care team, not to the value of any one profession.
Access to accurate testing differs by resource level as well. The Brazilian study described conventional methods as labor-intensive, time-consuming and costly in low-resource settings.[6] Hong Kong’s 97% screening adherence shows what a mature program can achieve.[14] In northern Guangdong, 1,352 of 1,437 GBS-positive women (94.1%) received intrapartum prophylaxis, so high delivery rates are possible in a regional hospital population.[7] The Dutch cohort’s 40% prophylaxis rate among eligible mothers shows how much can be missed when prevention relies on risk factors.[8]
Trust depends on equal protection. Stratifying offer rates, result timing, prophylaxis timing and antibiotic choice by site, care model, insurance and language lets leaders see whether every patient receives the same standard. Where gaps appear, the response is a pathway fix rather than a message to patients. Sharing those results with clinicians and community partners also shows that the organization measures fairness, not only volume. Equity review should include patients who arrive without prenatal care, since they are the most likely to have unknown status at delivery.

Human infrastructure
The people and teams who carry GBS prevention
GBS prevention depends on many roles: prenatal clinicians who offer the swab, laboratory scientists who process it, labor and delivery nurses who check status on arrival, and pharmacists and prescribers who choose the antibiotic. Each role touches the pathway at a different time, often weeks apart. In the GBS3 baseline and embedded qualitative studies, testing was acceptable to most women and health care professionals.[1] The study also examined barriers and facilitators to implementing different testing methods, including self-swabbing.[1]
Care models shape reliability. The Western Australian study found lower screening adherence in the midwifery-led model and discrepant adherence to intrapartum prophylaxis between the two models.[15] The comparison drew on 22,417 women who gave birth in five hospitals, a large base for comparing how teams perform.[15] The authors suggested that the findings could guide improvement of clinical protocols and planning of care.[15] For executives, the implication is that each care team needs the same reminders, order sets and result visibility.
Laboratory workload is a workforce question. Automated reading of chromogenic plates enabled release of negative results within 24 hours at the Geneva laboratory.[11] In Brazil, direct chromogenic plating was described as faster and simpler than broth-based methods.[6] Method choices can reduce manual steps for scarce microbiology staff and make results more predictable for clinical teams. Reliable methods also reduce repeat testing and calls between laboratory and clinical staff.
Intrapartum testing shifts work toward the delivery room. In the French combined screening program, PCR was performed in the delivery room when culture was negative or not done, and 99.0% of 15,013 women were screened by one method or the other.[12] At that level 3 center, rapid PCR became part of routine labor care.[4] Point-of-care testing adds tasks for nurses and midwives, so training, quality control and result documentation need clear owners.
Pharmacy and allergy expertise complete the team. In the safety-net study, most patients with low-risk allergy labels received alternative antibiotics.[13] Structured allergy assessment during prenatal care and pharmacist review of prophylaxis orders are natural places to assign that work. Leaders can ask, for each role, who covers the step on nights, weekends and high-volume days. Without that coverage, allergy review and timing checks are often the first tasks to slip when a unit is busy.
Executive guidance · Operating dashboard
Review reliability, not campaign activity alone.
Do not publish a number until the organization defines its numerator, denominator where relevant, owner, source system, exclusions, review cadence, and limits. The candidates below are management prompts, not benchmarks or reported results.
Four operating signals
Each signal pairs an executive question with one candidate local measure, set out below.
Executive guidance · Signal
Entry-point clarity
Can people and staff identify the approved first step without searching across conflicting instructions?
- Candidate local measure
- Locally defined contact, routing, and repeat-contact signals by channel and service.
Executive guidance · Signal
Ownership reliability
Does a specific team accept each request and make its status visible?
- Candidate local measure
- Requests without an owner, aged work, transfers, and escalations using locally approved definitions.
Executive guidance · Signal
Partner-route reliability
Do participating teams share one current route and understand who owns each dependency?
- Candidate local measure
- Locally defined conflicting instructions, unaccepted handoffs, unresolved dependencies, repeat contacts, and partner feedback.
Executive guidance · Signal
Improvement closure
Does the organization correct recurring friction and report what changed?
- Candidate local measure
- Selected barriers, assigned actions, completion status, and post-change review.
Figure 4
The operating system behind the dashboard
The four operating signals from this brief’s dashboard, each tied to the candidate owner named in the executive scorecard, around one accountable route. Drawn from the page’s original executive guidance.
Data note. Structural diagram; no measured values.
Limitation. Owners are candidates to be confirmed locally.
Figure data (4 rows)
| Operating signal | Candidate owner |
|---|---|
| Entry-point clarity | Executive sponsor and operational lead |
| Ownership reliability | Operational owner and participating teams |
| Partner-route reliability | Sending and receiving owners |
| Improvement closure | Improvement owner and executive sponsor |
Executive guidance · Handoff workflow
Transfer responsibility with acknowledgment and visibility.
A handoff is reliable only when the sending party knows who is expected to receive the work, the receiving party acknowledges responsibility, and any unresolved exception remains visible. Local policy and qualified judgment control the actual process.
How responsibility moves
Lane A
From message to accepted ownership
- Confirm the approved message and intended audience.
- Publish the actual entry point and receiving role.
- Acknowledge receipt using the locally approved method.
- Escalate when ownership or response remains unclear.
Lane B
From accepted ownership to verified follow-through
- Record the next accountable owner and visible status.
- Name the sending and receiving owners, shared information, current status, and unresolved dependency.
- Keep unresolved work visible across boundaries.
- Confirm closure or document the continuing exception.
Executive guidance · Executive scorecard
Connect operating signals to accountable executive review.
The scorecard keeps review focused on decisions. Leaders should set definitions locally, examine variation without overclaiming cause, and pair quantitative signals with the experience of people who use and operate the route.
Who reviews what
- Executive sponsor and operational lead
- Operational owner and participating teams
- Sending and receiving owners
- Improvement owner and executive sponsor
Candidate owners named in the scorecard, confirmed locally.
| Operating signal | Executive question | Candidate owner | Suggested review point |
|---|---|---|---|
| Entry-point clarity | Can people and staff identify the approved first step without searching across conflicting instructions? | Executive sponsor and operational lead | At campaign launch and close |
| Ownership reliability | Does a specific team accept each request and make its status visible? | Operational owner and participating teams | At a locally defined cadence |
| Partner-route reliability | Do participating teams share one current route and understand who owns each dependency? | Sending and receiving owners | At a locally defined cadence |
| Improvement closure | Does the organization correct recurring friction and report what changed? | Improvement owner and executive sponsor | Until action is verified |
Figure 5
Control points for a reliable GBS prevention pathway
| Control point | Risk if missing | Owner | Evidence of control |
|---|---|---|---|
| Screening offer built into the prenatal visit workflow | Eligible patients are never offered a swab | Ambulatory obstetrics medical director | Share of eligible patients offered and swabbed in the recommended window |
| Laboratory turnaround standard with result release to the labor record | Results are unavailable when the patient arrives in labor | Laboratory director with maternity informatics lead | Share of births with a result available at least four hours before birth |
| Rapid testing route for unknown status | Unscreened patients receive no testing or prophylaxis by default | Labor and delivery nurse manager | Share of births with unknown GBS status at delivery |
| Prophylaxis timing standard on admission | Antibiotics start too late to protect the newborn | Chief nursing officer and obstetric quality lead | Share of GBS-positive patients receiving prophylaxis at least four hours before birth |
| Prenatal penicillin allergy assessment | Low-risk allergy patients receive alternative antibiotics | Pharmacy and therapeutics committee | Share of low-risk allergy patients receiving standard prophylaxis |
| Stratified pathway review | Gaps by care model, site or insurance remain hidden | Chief medical officer and board quality committee | Quarterly report of offer, timing and antibiotic choice by subgroup |
Control points derived from the cited evidence [1], [4], [9], [12], [13], [15] and this brief’s executive guidance.
Data note. Each row is a control to verify, not a measured result.
Limitation. Owners and evidence of control must follow local policy and applicable requirements.
Public communication
Communicating with patients and clinicians about GBS testing
Patients need to understand why a late-pregnancy swab matters and what will happen with the result. The GBS3 qualitative work explored women’s views on testing methods and found testing acceptable to most women.[1] Of women offered a swab in the trial, 82% accepted, which suggests the clinical offer is the main communication task.[1] Clear prenatal materials can support that offer, but they cannot replace it.
Communicating results to the delivery team is as important as communicating with patients. When results are missing at admission, teams must rely on risk factors or rapid testing.[12] The French program that added delivery-room PCR found 294 additional cases among women with a prior negative culture.[12] The authors described the rapid method as feasible for routine use.[12] Result visibility in the labor record is therefore a communication control, not only an information technology task.
Clinicians also need accurate allergy information. The safety-net study classified allergy risk using the documented reaction in the electronic health record.[13] Its authors concluded that improved documentation of allergy type and severity is needed to expand adherence to guideline recommendations.[13] Fewer than 7% of patients in that cohort developed complications such as chorioamnionitis, endometritis or surgical site infection within 30 days.[13] Prenatal visits are an opportunity to clarify allergy history before labor, when time is short.
Public messages for Group B Strep Awareness Month should describe the test, its timing and what patients can ask at their next visit, without promising more than the system delivers. Communication about future options also needs care, because patients may hear about vaccines in the news and clinicians need consistent answers. In Dutch surveillance isolates, potential coverage was estimated at 97% for one candidate maternal vaccine and 99% for another.[10] Those are coverage estimates, not evidence that the vaccines prevent disease.[10]
Trust grows when the experience matches the message: the test is offered, the result is shared, and the delivery team acts on it in time. That includes telling patients when a result is pending and what will happen if labor starts first. Organizations that can show those steps working, with data, are better placed to communicate with confidence during the observance and after it.

Executive guidance · 90-day plan
Use 90 days to correct one visible operating barrier.
The time boxes below are a management framework, not a clinical timeline. Adjust them to risk, scope, governance, resources, stakeholder participation, and applicable review requirements.
Ninety days, three moves
- Days 1–30See the current route
- Days 31–60Build the reliable path
- Days 61–90Make the change visible
Days 1–30 · Listen and map
See the current route
- Name an executive sponsor and an operational owner.
- Listen to people using the route and representative frontline teams.
- Map how Group B Strep Awareness Month communications connect to real entry points, owners, transitions, and escalation.
- Select one recurring barrier that the organization can responsibly address.
Days 31–60 · Design and test
Build the reliable path
- Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal.
- Validate the design with every sending and receiving team involved.
- Test one internal or partner handoff and correct a verified communication, dependency, or ownership gap.
- Test the route in more than one representative setting or operating period where practical.
Days 61–90 · Implement and verify
Make the change visible
- Launch the redesigned route with a small set of locally defined measures.
- Review unresolved work and recurring friction using a learning approach.
- Correct implementation barriers and record who owns each remaining dependency.
- Report what changed, what evidence was reviewed, and what still requires live oversight.
Figure 6
The 90-day plan on one timeline
The 90-day plan from this brief drawn as a timeline: each action sits in the 30-day window the plan assigns it. The full wording of each action is in the figure data and in the plan above.
Data note. Time boxes are a management framework, not a clinical timeline.
Limitation. Durations are uniform 30-day windows; real tasks may span windows.
Figure data (12 rows)
| Window | Action |
|---|---|
| Days 1–30 · Listen and map | Name an executive sponsor and an operational owner. |
| Days 1–30 · Listen and map | Listen to people using the route and representative frontline teams. |
| Days 1–30 · Listen and map | Map how Group B Strep Awareness Month communications connect to real entry points, owners, transitions, and escalation. |
| Days 1–30 · Listen and map | Select one recurring barrier that the organization can responsibly address. |
| Days 31–60 · Design and test | Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal. |
| Days 31–60 · Design and test | Validate the design with every sending and receiving team involved. |
| Days 31–60 · Design and test | Test one internal or partner handoff and correct a verified communication, dependency, or ownership gap. |
| Days 31–60 · Design and test | Test the route in more than one representative setting or operating period where practical. |
| Days 61–90 · Implement and verify | Launch the redesigned route with a small set of locally defined measures. |
| Days 61–90 · Implement and verify | Review unresolved work and recurring friction using a learning approach. |
| Days 61–90 · Implement and verify | Correct implementation barriers and record who owns each remaining dependency. |
| Days 61–90 · Implement and verify | Report what changed, what evidence was reviewed, and what still requires live oversight. |
Executive guidance · Leadership close
Pair recognition with a system people can trust.
Recognition matters. It becomes durable when leaders also listen, clarify the route, support the people operating it, close an identified gap, and report the result without claiming more than the evidence supports.
Leadership commitment
Connect the message to one usable, measured, and sustained operating change.
Executive action kit · Month observance
Turn Group B Strep Awareness Month into accountable action.
Move from recognition activity to a visible operating route with named owners and closed loops.
Leadership focus
Use this observance to examine trustworthy information, prevention access, and community connection. Select one verified barrier, assign an accountable owner, and carry the improvement beyond the campaign window.
Workforce lens
Ask whether staffing, role clarity, training, tools, workload, and escalation support the people operating the information, access, coordination, and follow-through pathway.
Patient and community lens
Make the approved first step clear. Test whether a person can move from information to an acknowledged next action without navigating conflicting instructions.
Equity and access lens
Review language, disability, transportation, digital access, geography, trust, and other barriers using protected feedback and locally appropriate data.
Five-minute briefing
Inspect the operating sequence
Listen with people using the pathway, frontline teams, operational leaders, and community partners. Find one a message, request, referral, or handoff that does not reach an accountable owner, then test the locally approved route from entry through acknowledged follow-through.
- Listen
- Clarify entry
- Coordinate the partner route
- Protect transitions
- Verify and learn
Leadership actions for this week
- Name an executive sponsor and frontline operating owner.
- Ask people using and operating the pathway where ownership becomes unclear.
- Test one representative route from first question to acknowledged next step.
- Select one barrier that can be corrected without overstating the evidence.
- Set a review date and define how completion will be verified.
Candidate measures
Define every numerator, denominator where relevant, owner, data source, exclusions, cadence, and limitation locally. These are management prompts, not external benchmarks.
- Locally defined contact, routing, and repeat-contact signals by channel and service.
- Requests without an owner, aged work, transfers, and escalations using locally approved definitions.
- Locally defined conflicting instructions, unaccepted handoffs, unresolved dependencies, repeat contacts, and partner feedback.
Department readiness checklist
- The public and staff entry points match the actual approved process.
- A specific role accepts each request, referral, or escalation.
- Handoffs include acknowledgment and a visible unresolved state.
- Language, disability, digital, transportation, and trust barriers receive explicit review.
- Communications do not introduce unsupported themes, statistics, or clinical advice.
- A named leader will review what changed after the observance.
Intended audiences
- Executive and Operational Leaders
- Public Health and Community Partners
Staff communication template
During Group B Strep Awareness Month, our organization will connect awareness with a practical review of the information, access, coordination, and follow-through pathway. Use approved information, identify the correct entry point, confirm ownership when work moves, protect privacy, and escalate unresolved barriers through local channels.
Community communication template
Group B Strep Awareness Month is an opportunity to share trustworthy information and make the next step easier to find. Use our approved channels for information and support. If a request changes hands, our goal is to keep ownership and follow-through visible.
Measurement worksheet
- Signal
- What observable condition will show whether the route works?
- Definition
- What is included, excluded, and counted?
- Owner
- Who reviews the signal and acts on exceptions?
- Cadence
- When will leaders review it?
- Equity check
- Which differences require protected, locally appropriate review?
- Closure
- What evidence will confirm the improvement was completed?
- Editorial review
- Completed
- Source records
- 2 listed under Authoritative resources
- Review standard
- Sourced facts remain separated from original executive guidance
- Clinical boundary
- No new statistical or clinical claim was added by this action kit
Sources and content boundary
Authoritative resources
- Observance source: groupbstrepinternational.org
- 2026 healthcare observances calendar: healthgrades.com
Use note: All operating models, measures, scorecard questions, and action steps are original executive guidance. This article supports leadership planning and education. It does not replace clinical judgment, emergency procedures, legal advice, professional standards, organizational policy, or applicable federal, state, and local requirements.
Peer-reviewed references
References
Fifteen peer-reviewed sources, newest first. Each was individually verified through authenticated academic research databases. Bracketed numbers in the text link here; the original executive guidance on this page carries no citations because it is guidance, not a sourced claim. Sources last checked in those databases on .
- 1.Daniels JP, Walker KF, Bradshaw L, Dorling J, Ojha S, Gray J, et al. Universal maternal testing for group B streptococcus in late pregnancy: process outcomes and alongside qualitative study for the GBS3 trial. Early Human Development. 2026;213. https://doi.org/10.1016/j.earlhumdev.2025.106442
- 2.Germ J, Maver Vodičar P. Optimal screening strategies, colonization rates, and antimicrobial resistance within a newly implemented organized group B Streptococcus screening program in Slovenia. Diagnostic Microbiology and Infectious Disease. 2026;116(3):117508. https://doi.org/10.1016/j.diagmicrobio.2026.117508
- 3.Martins P, Mantopoulos T, Cheng M, Doshi S, Messai I, Chahar A, et al. Costs and outcomes of group B Streptococcus (GBS) screening strategies in France for prevention of neonatal early-onset GBS disease. The Journal of Maternal-Fetal & Neonatal Medicine. 2026;39(1):2712110. https://doi.org/10.1080/14767058.2026.2712110
- 4.Dentaud L, Gascoin G, Paret L, Brehin C, Marechal O, Vayssiere C, et al. Evaluation of rapid intrapartum PCR screening for Group B Streptococcus in mothers of full-term newborns at a level 3 maternity center. The Journal of Maternal-Fetal & Neonatal Medicine. 2026;39(1):2660013. https://doi.org/10.1080/14767058.2026.2660013
- 5.Utaipatanacheep P, Chatsuwan T, Thuwanut P, Chaithongwongwatthana S. Targeted screening for the detection of group B Streptococcus during the intrapartum period by real-time polymerase chain reaction. International Journal of Infectious Diseases. 2026;164:108415. https://doi.org/10.1016/j.ijid.2026.108415
- 6.Costa NS, Rio-Tinto A, Santana JDD, Garcia JFFM, Pinto IBF, Barros LG, et al. Improved detection of group B Streptococcus in rectovaginal samples of pregnant individuals in Brazil using chromogenic medium. Microbiology Spectrum. 2026;14(2):e0245925. https://doi.org/10.1128/spectrum.02459-25
- 7.Ma Z, Fan S, Lin Z, Huang W. Group B streptococcus colonization and adverse pregnancy outcomes in pregnant women: a population-based study in northern Guangdong, China. BMC Pregnancy and Childbirth. 2026;26(1). https://doi.org/10.1186/s12884-026-09065-6
- 8.Groenveld MA, Visser DH, Brouwer MC, Jamrozy D, van Sorge NM, Snoek L, et al. Clinical characteristics, outcomes and molecular epidemiology of group B streptococcal disease in young infants in the Netherlands. Journal of Infection. 2026;93(3). https://doi.org/10.1016/j.jinf.2026.106815
- 9.Alayed N, AlOthman H, Almalki A, Asfina KN, Khalil N, Somily A, et al. The proportion of GBS-positive mothers among the screened population and outcomes of maternal Group B streptococcus colonization at King Saud University Medical City: a retrospective cohort study. Annals of Saudi Medicine. 2026;46(4):268-276. https://doi.org/10.5144/0256-4947.2026.268
- 10.van Beek R, Bekker V, van den Berg M, Blok GJ, Breukels M, Brouwer AFJ, et al. Group B streptococcal disease in infants 0–3 months in The Netherlands, 1987–2023: a nationwide genomic and epidemiological surveillance study. The Lancet Regional Health – Europe. 2026;66. https://doi.org/10.1016/j.lanepe.2026.101711
- 11.Cherkaoui A, Renzi G, Schrenzel J. PhenoMATRIX™ for the screening of Group B Streptococcus (GBS) carriage in pregnant women: ready to get rid of the LIM broth?. European Journal of Clinical Microbiology & Infectious Diseases. 2025;44(1):63-69. https://doi.org/10.1007/s10096-024-04985-7
- 12.Abgral M, Albersammer L, Carrara J, Guillet-Caruba C, Benachi A, De Luca D, et al. Impact of combined vaginal group B Streptococcus screening (culture and rapid PCR) in pregnant women on neonatal morbidity and mortality. Journal of Infection and Public Health. 2025;18(10):102883. https://doi.org/10.1016/j.jiph.2025.102883
- 13.Frappa KE, Fabbri S, Rockhill KM, Shihadeh KC, Jenkins TC, McClelland S. Penicillin allergies and selection of intrapartum antibiotic prophylaxis against group B Streptococcus at a safety-net institution. Journal of Perinatal Medicine. 2025;53(5):624-629. https://doi.org/10.1515/jpm-2024-0596
- 14.Fung TY, Sahota DS. How can we reduce neonatal sepsis after universal group B streptococcus screening?. BMC Pregnancy and Childbirth. 2024;24(1):586. https://doi.org/10.1186/s12884-024-06791-7
- 15.Pangerl S, Sundin D, Geraghty S. Adherence to screening and management guidelines of maternal Group B Streptococcus colonization in pregnancy. Journal of Advanced Nursing. 2022;78(10):3247-3260. https://doi.org/10.1111/jan.15249
Claim-to-source matrix
What each source supports
Every sourced claim in the new sections maps to the references that support it, the section where it is used, and the limitation a reader should keep in mind. Original executive guidance carries no sources because it is guidance, not a finding.
| Claim group | Sources | Years | Used in | Limitation |
|---|---|---|---|---|
| Colonization prevalence and antimicrobial resistance in organized screening | [2] [7] [15] | 2026, 2022 | Current evidence | Single-laboratory, single-hospital and regional administrative data; methods differ across settings. |
| Colonization and adverse pregnancy and neonatal outcomes | [7] [14] | 2026, 2024 | Current evidence | Observational hospital cohorts; association, not causation. |
| Infant GBS disease incidence, outcomes and serotypes | [8] [10] | 2026 | Current evidence | Dutch surveillance and cohort data; culture-confirmed cases only. |
| Process completion of universal testing in the GBS3 trial | [1] | 2026 | Continuum of care | Record review of about 130 records per unit; process outcomes, not clinical effectiveness. |
| Timing of intrapartum prophylaxis and neonatal outcomes | [9] [14] | 2026, 2024 | Continuum of care | Single-center retrospective cohorts with small numbers of events. |
| Intrapartum PCR for unscreened and culture-negative women | [4] [12] | 2026, 2025 | Continuum of care | Single-center French before-and-after and retrospective designs. |
| PCR, chromogenic media and automation for detection and turnaround | [5] [6] [11] | 2026, 2025 | Access | Laboratory method comparisons in single centers; 174 participants in the PCR study. |
| Cost and outcome modeling of screening strategies | [3] | 2026 | Access | Decision-analytic model from a French health system perspective; modeled, not observed, outcomes. |
| Penicillin allergy labels and inappropriate alternative prophylaxis | [13] | 2025 | Equity and trust | Single U.S. safety-net institution; 86 colonized patients with low-risk allergies. |
| Screening adherence by model of care | [15] | 2022 | Human infrastructure | Administrative data from five Western Australian hospitals, 2015 to 2019. |
| Potential maternal vaccine coverage | [10] | 2026 | Public communication | Strain coverage estimates, not vaccine effectiveness. |

About the author
Greg Wahlstrom
MBAHCM
President and Chief Executive Officer, The Healthcare Executive
View Greg’s profile©2014 – 2026 The Healthcare Executive. All rights reserved.

